Heron Therapeutics Inc HRTX:NASDAQ

Last Price$18.89Cboe Real-Time Last Sale as of 3:50PM ET 6/03/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.43(2.33%)
Bid (Size)$18.90 (100)
Ask (Size)$18.98 (100)
Day Low / High$18.41 - 18.90
Volume584.0 K
 

View Biotechnology IndustryPeer Comparison as of 06/03/2020

 

Heron Therapeutics Inc ( NASDAQ )

Price: $18.89
Change: +0.43 (2.33%)
Volume: 584.0 K
3:50PM ET 6/03/2020
 
 

Sangamo Therapeutics Inc ( NASDAQ )

Price: $11.57
Change: -0.23 (1.95%)
Volume: 1.0 M
3:53PM ET 6/03/2020
 
 

Adverum Biotechnologies Inc ( NASDAQ )

Price: $20.97
Change: -0.15 (0.71%)
Volume: 373.6 K
3:47PM ET 6/03/2020
 
 

Akebia Therapeutics Inc ( NASDAQ )

Price: $11.89
Change: +0.58 (5.13%)
Volume: 1.4 M
3:52PM ET 6/03/2020
 
 

Twist Bioscience Corp ( NASDAQ )

Price: $36.85
Change: -2.08 (5.34%)
Volume: 552.0 K
3:46PM ET 6/03/2020
 

Read more news Recent News

Analyst Actions: Guggenheim Starts Heron Therapeutics at Buy With $24 Price Target
9:28AM ET 5/27/2020 MT Newswires

Heron Therapeutics (HRTX) has an average analyst rating of buy, with an average price target of $42. Price: 19.05, Change: +0.61, Percent Change: +3.31 ...

Heron Therapeutics Commences Clinical Trial of Post-Operative Pain Medication
9:32AM ET 5/18/2020 MT Newswires

Heron Therapeutics (HRTX) said Monday that it has begun a phase 1b/2 clinical trial of HTX-034, the company's next-generation product for the treatment of...

Heron Therapeutics Q1 Loss Narrows, Revenue Declines
12:18PM ET 5/06/2020 MT Newswires

Heron Therapeutics (HRTX) on Wednesday posted a Q1 loss of $0.57, narrowing from $0.80 loss a year ago. Analysts polled by Capital IQ had expected a loss...

Heron Therapeutics Slips After Posting Worse-Than-Expected Q4 Loss Per Share; Revenue Tops Consensus
2:28PM ET 3/02/2020 MT Newswires

Heron Therapeutics (HRTX) on Monday posted a Q4 net loss of $0.65 per share, compared with a net loss of $0.63 per share a year earlier and wider than the...

Company Profile

Business DescriptionHeron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA. View company web site for more details
Address4242 Campus Point Court
San Diego, California 92121
Phone+1.858.251.4400
Number of Employees198
Recent SEC Filing05/18/20208-K
President, Chief Executive Officer & DirectorBarry D. Quart
Chief Financial Officer & Senior VP-FinanceRobert E. Hoffman
Chief Scientific Officer & SVP-PharmaceuticalThomas B. Ottoboni
Chief Medical OfficerChris M. Storgard

Company Highlights

Price Open$18.48
Previous Close$18.46
52 Week Range$9.60 - 26.81
Market Capitalization$1.7 B
Shares Outstanding90.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.27
Beta vs. S&P 500N/A
Revenue$77.5 M
Net Profit Margin-138.31%
Return on Equity-56.85%

Analyst Ratings as of 05/22/2020

Buy
10
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset